Psychedelics have demonstrated significant progress, with promising data and increased interest from large companies, ...

In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular ...

PE: How will FDA's Priority Review Program impact domestic manufacturing? Conrad: A company is not going to de novo set up a new US-based manufacturing site just for this voucher. They cost billions ...

Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...